This website is intended for US healthcare professionals.

background background

Dosing and
Administration

Actor portrayal

Redefining HAE attack management1

EKTERLY is the first and only oral treatment for HAE that lets patients treat at attack recognition1,2

Not actual size

Always ready to treat1

Watch icon

anytime

No preparation or setup required

Location icon

anywhere

Easily stored in a pocket, wallet, or bag

  • May be taken with or without food1

  • Smooth, film-coated tablets for
    easy swallowing1,3

  • No refrigeration required1

Not actual size

One 600-mg dose can provide symptom relief1

Each carton of EKTERLY
contains 4 individual
blister cards1

  • One 600-mg dose is two 300-mg tablets
  • EKTERLY 300 mg is not a recommended dose for treatment
  • Patients can take an additional dose
    of EKTERLY 3 hours after their first dose, based on how they feel during an attack1,4
  • The maximum dose in a 24-hour period is 4 tablets (1200 mg)1
View study design link
Quote

“If the treatment guidelines aren’t realistic for
patients or if patients have certain barriers
that they’re not able
to overcome, we have
to offer an option that’s more [appropriate]
to patients’ lives.”

—Douglas Jones, MD
Allergy/Immunology Specialist

Hypothetical EKTERLY® (sebetralstat) patient sitting outside with a drink Hypothetical EKTERLY® (sebetralstat) patient sitting outside with a drink
UP NEXT:
Efficacy and Safety Right arrow
Actor portrayal

HAE=hereditary angioedema.

References:

1. EKTERLY. Package insert. KalVista Pharmaceuticals, Inc.; 2025.
2. KalVista Pharmaceuticals announces FDA approval of EKTERLY (sebetralstat), first and only oral on demand treatment for hereditary angioedema. Published July 2025. Accessed July 2025. 3. Ershad AL, Rajabi-Siahboomi A, Missaghi S, Kirby D, Mohammed AR. Multi-analytical framework to assess the in vitro swallowability of solid oral dosage forms targeting patient acceptability and adherence. Pharmaceutics. 2021;13(3):411. doi:10.3390/pharmaceutics13030411 4. Riedl MA, Farkas H, Aygören-Pürsün E, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32-43. doi:10.1056/NEJMoa2314192

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION

Adverse reactions: The most commonly reported adverse reaction was headache.

Drug interactions: EKTERLY is a substrate of CYP3A4. Concomitant use of EKTERLY with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions. Avoid use of EKTERLY with strong CYP3A4 inhibitors and reduce the dose of EKTERLY to one dose of 300 mg (one tablet) with moderate CYP3A4 inhibitors. Concomitant use of EKTERLY with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. The use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.

Use in specific populations: Avoid use of EKTERLY in patients with severe hepatic impairment (Child-Pugh Class C). The recommended dosage of EKTERLY is one dose of 300 mg (one tablet) in patients with moderate hepatic impairment (Child-Pugh Class B).

There are no available data on EKTERLY in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no data on the presence of sebetralstat or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production.

The safety and effectiveness of EKTERLY in pediatric patients aged under 12 years of age have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact KalVista Pharmaceuticals, Inc. at 1-855-258-4782 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.